{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:51:10Z","timestamp":1792144270536,"version":"4.4.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,6,15]],"date-time":"2011-06-15T00:00:00Z","timestamp":1308096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,6,15]],"date-time":"2011-06-15T00:00:00Z","timestamp":1308096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Sleep Med"],"published-print":{"date-parts":[[2011,6,15]]},"DOI":"10.5664\/jcsm.1074","type":"journal-article","created":{"date-parts":[[2011,6,14]],"date-time":"2011-06-14T15:32:39Z","timestamp":1308065559000},"page":"282-292","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Gabapentin Enacarbil in Subjects with Restless Legs Syndrome"],"prefix":"10.1007","volume":"7","author":[{"given":"Daniel O.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald B.","family":"Ziman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Thomas","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Steven","family":"Poceta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur S.","family":"Walters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald W.","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"XP053 Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,6,15]]},"reference":[{"key":"BF0703009_CR1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1389-9457(03)00010-8","volume":"4","author":"RP Allen","year":"2003","unstructured":"Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisir J. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003;4:101\u201319.","journal-title":"Sleep Med"},{"key":"BF0703009_CR2","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/archinte.165.11.1286","volume":"165","author":"RP Allen","year":"2005","unstructured":"Allen RP, Walters AS, Montplaisir J, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005;165:1286\u201392.","journal-title":"Arch Intern Med"},{"key":"BF0703009_CR3","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.sleep.2004.03.006","volume":"5","author":"W Hening","year":"2004","unstructured":"Hening W, Walters AS, Allen RP, Montplaisir J, Myers A, Ferini-Strambi L. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med 2004;5:237\u201346.","journal-title":"Sleep Med"},{"key":"BF0703009_CR4","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.sleep.2004.04.004","volume":"5","author":"CA Kushida","year":"2004","unstructured":"Kushida CA, Allen RP, Atkinson MJ. Modeling the causal relationships between symptoms associated with restless legs syndrome and the patient-reported impact of RLS. Sleep Med 2004;5:485\u20138.","journal-title":"Sleep Med"},{"key":"BF0703009_CR5","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1001\/archneur.61.9.1393","volume":"61","author":"W Ondo","year":"2004","unstructured":"Ondo W, Romanyshyn J, Vuong KD, Lai D. Long-term treatment of restless legs syndrome with dopamine agonists. Arch Neurol 2004;61:1393\u20137.","journal-title":"Arch Neurol"},{"key":"BF0703009_CR6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.sleep.2003.07.005","volume":"5","author":"JW Winkelman","year":"2004","unstructured":"Winkelman JW, Johnston L. Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). Sleep Med 2004;5:9\u201314.","journal-title":"Sleep Med"},{"key":"BF0703009_CR7","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.amjmed.2006.11.005","volume":"120","author":"JW Winkelman","year":"2007","unstructured":"Winkelman JW. A better future for patients with restless legs syndrome. Am J Med 2007;120:S28\u20139.","journal-title":"Am J Med"},{"key":"BF0703009_CR8","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1212\/WNL.59.10.1573","volume":"59","author":"D Garcia-Borreguero","year":"2002","unstructured":"Garcia-Borreguero D, Larrosa O, de la Llave Y, Verger K, Masramon X, Hernandez G. Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology 2002;59:1573\u20139.","journal-title":"Neurology"},{"key":"BF0703009_CR9","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1159\/000072882","volume":"48","author":"S Happe","year":"2003","unstructured":"Happe S, Sauter C, Klosch G, Saletu B, Zeitlhofer J. Gabapentin versus ropinirole in the treatment of idiopathic restless legs syndrome. Neuropsychobiology 2003;48:82\u20136.","journal-title":"Neuropsychobiology"},{"key":"BF0703009_CR10","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1212\/WNL.57.9.1717","volume":"57","author":"S Happe","year":"2001","unstructured":"Happe S, Klosch G, Saletu B, Zeitlhofer J. Treatment of idiopathic restless legs syndrome (RLS) with gabapentin. Neurology 2001;57:1717\u20139.","journal-title":"Neurology"},{"key":"BF0703009_CR11","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/j.1528-1157.1997.tb01223.x","volume":"38","author":"RL Kriel","year":"1997","unstructured":"Kriel RL, Birnbaum AK, Cloyd JC, Ricker BJ, Jones Saete C, Caruso KJ. Failure of absorption of gabapentin after rectal administration. Epilepsia 1997;38:1242\u20134.","journal-title":"Epilepsia"},{"key":"BF0703009_CR12","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1023\/A:1018951214146","volume":"10","author":"BH Stewart","year":"1993","unstructured":"Stewart BH, Kugler AR, Thompson PR, Bockbrader HN. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm Res 1993;10:276\u201381.","journal-title":"Pharm Res"},{"key":"BF0703009_CR13","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0920-1211(98)00020-5","volume":"31","author":"BE Gidal","year":"1998","unstructured":"Gidal BE, DeCerce J, Bockbrader HN, et al. Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsy. Epilepsy Res 1998;31:91\u20139.","journal-title":"Epilepsy Res"},{"key":"BF0703009_CR14","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0920-1211(00)00117-0","volume":"40","author":"BE Gidal","year":"2000","unstructured":"Gidal BE, Radulovic LL, Kruger S, Rutecki P, Pitterle M, Bockbrader HN. Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability. Epilepsy Res 2000;40:123\u20137.","journal-title":"Epilepsy Res"},{"key":"BF0703009_CR15","first-page":"830","volume":"36","author":"KO Vollmer","year":"1986","unstructured":"Vollmer KO, von Hodenberg A, Kolle EU. Pharmacokinetics and metabolism of gabapentin in rat, dog and man. Arzneimittelforschung 1986;36:830\u20139.","journal-title":"Arzneimittelforschung"},{"key":"BF0703009_CR16","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1124\/jpet.104.067959","volume":"311","author":"KC Cundy","year":"2004","unstructured":"Cundy KC, Annamalai T, Bu L, et al. XP13512 [(+\/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. J Pharmacol Exp Ther 2004;311:324\u201333.","journal-title":"J Pharmacol Exp Ther"},{"key":"BF0703009_CR17","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1124\/jpet.104.067934","volume":"311","author":"KC Cundy","year":"2004","unstructured":"Cundy KC, Branch R, Chernov-Rogan T, et al. XP13512 [(+\/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters. J Pharmacol Exp Ther 2004;311:315\u201323.","journal-title":"J Pharmacol Exp Ther"},{"key":"BF0703009_CR18","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1177\/0091270008322909","volume":"48","author":"KC Cundy","year":"2008","unstructured":"Cundy KC, Sastry S, Luo W, Zou J, Moors TL, Canafax DM. Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin. J Clin Pharmacol 2008;48:1378\u201388.","journal-title":"J Clin Pharmacol"},{"key":"BF0703009_CR19","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1016\/j.clinthera.2009.07.026","volume":"31","author":"R Lal","year":"2009","unstructured":"Lal R, Sukbuntherng J, Luo W, et al. Pharmacokinetics of single escalating doses of gabapentin enacarbil in healthy adult volunteers: a randomized sequence, double-blind, placebo-controlled, crossover study. Clin Ther 2009;31:1776\u201386.","journal-title":"Clin Ther"},{"key":"BF0703009_CR20","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1212\/01.wnl.0000341770.91926.cc","volume":"72","author":"CA Kushida","year":"2009","unstructured":"Kushida CA, Becker PM, Ellenbogen AL, Canafax DM, Barrett RW, the XP052 Study Group. Randomized, double-blind, placebo-controlled trial of XP13512\/GSK1838262 in patients with RLS. Neurology 2009;72:439\u201346.","journal-title":"Neurology"},{"key":"BF0703009_CR21","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/WNF.0b013e3181b3ab16","volume":"32","author":"AS Walters","year":"2009","unstructured":"Walters AS, Ondo WG, Kushida CA, et al. Gabapentin enacarbil in restless legs syndrome: a phase 2b, two-week, randomized, double-blind, placebo-controlled trial. Clin Neuropharmacol 2009;32:311\u201320.","journal-title":"Clin Neuropharmacol"},{"key":"BF0703009_CR22","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1389-9457(02)00258-7","volume":"4","author":"AS Walters","year":"2003","unstructured":"Walters AS, LeBrocq C, Dhar A, et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 2003;4:121\u201332.","journal-title":"Sleep Med"},{"key":"BF0703009_CR23","unstructured":"World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects: 2004 Revision. 2004."},{"key":"BF0703009_CR24","first-page":"218","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"W Guy","year":"1976","unstructured":"National Institute of Mental Health (NIMH). Guy W. Early Clinical Drug Evaluation Unit (ECDEU). Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology Rockville, MD: NIMH, USA; 1976:218\u201322."},{"key":"BF0703009_CR25","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0022-3999(02)00330-6","volume":"53","author":"J Backhaus","year":"2002","unstructured":"Backhaus J, Junghanns K, Broocks A, Riemann D, Hohagen F. Test-retest reliability and validity of the Pittsburgh Sleep Quality Index in primary insomnia. J Psychosom Res 2002;53:737\u201340.","journal-title":"J Psychosom Res"},{"key":"BF0703009_CR26","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1365-2869.1994.tb00114.x","volume":"3","author":"TH Monk","year":"1994","unstructured":"Monk TH, Reynolds CFIII Kupfer DJ, et al. The Pittsburgh Sleep Diary. J Sleep Res 1994;3:111\u201320.","journal-title":"J Sleep Res"},{"key":"BF0703009_CR27","first-page":"235","volume-title":"Measuring functioning and well-being. The Medical Outcomes Study approach","author":"RD Hays","year":"1992","unstructured":"Hays RD, Stewart AL, Stewart AL, Ware JEJ. Sleep measures. Measuring functioning and well-being. The Medical Outcomes Study approach Durham and London, UK: Duke University Press; 1992:235\u201359."},{"key":"BF0703009_CR28","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.sleep.2008.06.003","volume":"10","author":"RP Allen","year":"2008","unstructured":"Allen RP, Kosinski M, Hill-Zabala CE, Calloway MO. Psychometric evaluation and tests of validity of the Medical Outcomes Study 12-item Sleep Scale (MOS sleep). Sleep Med 2008;10:531\u20139.","journal-title":"Sleep Med"},{"key":"BF0703009_CR29","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","volume":"14","author":"MW Johns","year":"1991","unstructured":"Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991;14:540\u20135.","journal-title":"Sleep"},{"key":"BF0703009_CR30","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/sleep\/32.2.159","volume":"32","author":"CA Kushida","year":"2009","unstructured":"Kushida CA, Walters AS, Becker P, et al. A randomized, double-blind, placebo-controlled, crossover study of XP13512\/GSK1838262 in the treatment of patients with primary restless legs syndrome. Sleep 2009;32:159\u201368.","journal-title":"Sleep"},{"key":"BF0703009_CR31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4065\/81.1.17","volume":"81","author":"RK Bogan","year":"2006","unstructured":"Bogan RK, Fry JM, Schmidt MH, Carson SW, Ritchie SY. Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc 2006;81:17\u201327.","journal-title":"Mayo Clin Proc"},{"key":"BF0703009_CR32","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.sleep.2008.09.001","volume":"9","author":"L Ferini-Strambi","year":"2008","unstructured":"Ferini-Strambi L, Aarskog D, Partinen M, et al. Effect of pramipexole on RLS symptoms and sleep: A randomized, double-blind, placebo-controlled trial. Sleep Med 2008;9:874\u201381.","journal-title":"Sleep Med"},{"key":"BF0703009_CR33","first-page":"92","volume":"75","author":"C Trenkwalder","year":"2004","unstructured":"Trenkwalder C, Garcia-Borreguero D, Montagna P, et al. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry 2004;75:92\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"BF0703009_CR34","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/mds.20257","volume":"19","author":"AS Walters","year":"2004","unstructured":"Walters AS, Ondo WG, Dreykluft T, Grunstein R, Lee D, Sethi K. Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov Disord 2004;19:1414\u201323.","journal-title":"Mov Disord"},{"key":"BF0703009_CR35","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1212\/01.wnl.0000231513.23919.a1","volume":"67","author":"JW Winkelman","year":"2006","unstructured":"Winkelman JW, Sethi KD, Kushida CA, et al. Efficacy and safety of pramipexole in restless legs syndrome. Neurology 2006;67:1034\u201339.","journal-title":"Neurology"}],"container-title":["Journal of Clinical Sleep Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.5664\/JCSM.1074.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.5664\/JCSM.1074\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.aasmnet.org\/jcsm\/viewabstract.aspx?pid=28164","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.5664\/JCSM.1074.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T08:03:44Z","timestamp":1770365024000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.5664\/JCSM.1074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,15]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,6,15]]}},"alternative-id":["BF0703009"],"URL":"https:\/\/doi.org\/10.5664\/jcsm.1074","relation":{},"ISSN":["1550-9389","1550-9397"],"issn-type":[{"value":"1550-9389","type":"print"},{"value":"1550-9397","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,15]]},"assertion":[{"value":"1 February 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2010","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2010","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2011","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}